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Background: Diabetes remains a major health problem worldwide. Low-risk low-cost alternatives to pharmaceutical
interventions are needed where lifestyle modifications have failed. We conducted a double-blind randomised
placebo controlled trial to investigate the efficacy of a Chinese herbal formula, Jiangtang Xiaozhi, in treating
impaired glucose control and insulin resistance in persons with prediabetes and controlled diabetes.
Methods: Seventy-one patients with prediabetes or ‘controlled’ diabetes were randomised to receive 3 capsules of
Jiangtang Xiaozhi (n = 39) or placebo (n = 32) three times daily for 16 weeks with a follow up eight weeks later
(week 24). The primary outcome was change in glycaemic control as evidenced by fasting blood glucose (FBG),
post-prandial plasma glucose and glycosylated haemoglobin (HbA1c). Other measures included change in fasting
insulin, insulin resistance and sensitivity, lipids, C-reactive protein (CRP), body mass index (BMI), waist girth, blood
pressure (BP), health related quality of life (HRQoL) and safety. Analysis of covariance (ANCOVA) was used to model
outcomes at 16 weeks, by treatment group corrected for baseline level of the outcome variable.
Results: In patients receiving Jiangtang Xiaozhi, FBG was not significantly different (p = 0.73) compared to placebo
after 16 weeks of treatment (6.3 ± 1.1 mmol/L vs 6.7 ± 1.3 mmol/L). There was a significant difference (p = 0.04) in
the mean levels of fasting insulin between the treatment group (11.6 ± 5.5 mmol/L) and the placebo group
(22.1 ± 25.9 mmol/L). Insulin resistance slightly decreased in the treatment group (1.58 ± 0.74) compared to that of
the placebo group (2.43 ± 1.59) but this change did not reach statistical significance (p = 0.06). Patients taking
Jiangtang Xiaozhi had a significant improvement in high-density lipoprotein (HDL) level compared to the placebo
group at week 16 (p = 0.03). Mean levels of cholesterol, triglycerides, BMI, waist-girth, HRQoL, BP, CRP and insulin
sensitivity were not significantly different between the two groups. The herbal medicine was well tolerated.
Conclusions: In the current study, the 16 week Jiangtang Xiaozhi treatment did not lower fasting blood glucose,
but it improved serum insulin and HDL cholesterol in a Western population with prediabetes or controlled diabetes.
Our trial may have been underpowered. Dosage needs to be considered before commencing a longer adequately
powered trial.
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Worldwide it is estimated 285 million adults - equivalent
to 6.4% of the population aged 20 to 79 yrs - have diabetes
[1]. A further 344 million have impaired glucose tolerance
(IGT) [1]. Over time, the glucose tolerance of many of
these individuals will deteriorate and they will be diagnosed
with diabetes. Impaired glucose tolerance, independent of
diabetes, carries an increased risk of cardiovascular disease
and all-cause mortality [2-4]. At present, the best course of
action to reduce higher than normal blood sugar is to mod-
ify diet and increase physical activity. For some, rigorous
and sustained behavioural change isn’t enough. In these
cases pharmaceutical interventions such as metformin may
be needed to delay or suppress the onset of diabetes.
But this is not always an adequate long-term solution. A
Kaplan-Meier analysis showed a cumulative incidence of
monotherapy failure at 5 years of 15% with rosiglitazone,
21% with metformin and 34% with glyburide [5]. Low-risk
low-cost alternatives to pharmaceutical interventions are
clearly needed where lifestyle modifications have failed to
adequately improve glucose tolerance.
Individuals with diabetes are 1.6 times more likely to
use complementary and alternative medicine (CAM) than
individuals without diabetes [6]. However these CAM
interventions need to be tested in clinical trials to demon-
strate efficacy and safety. Chinese herbal medicines have
long been used for the treatment of IGT and diabetes in
China, Korea and Japan, with anecdotal evidence of their
effectiveness. In a meta-analysis of eight trials, those
receiving Chinese herbal medicines with lifestyle modifica-
tion were more than twice as likely to have their fasting
plasma glucose levels return to normal compared to those
receiving lifestyle modification alone [7]. Those receiving
Chinese herbs were less likely to progress to diabetes over
the duration of the trials. These trials were at considerable
risk of bias due problems with randomisation, allocation
concealment or blinding. Nonetheless the strength of the
findings warrants further investigation.
Jiangtang Xiaozhi is a Chinese herbal formulation
based on traditional Chinese medicine principles, modern
research and clinical experience. Animal studies and a small
clinical trial of Jiangtang Xiaozhi, along with studies of the
effects of the individual herbs, have produced encouraging
results [8-10]. In this article we report the findings
from a randomized controlled trial evaluating the effect of
Jiangtang Xiaozhi on blood glucose, insulin and lipids in
people with IGT and controlled diabetes.
Methods
Patient and recruitment
Individuals were recruited across Sydney and the Central
Coast of NSW, Australia through media (radio, television,
newspapers), by approaching general practitioners, direct
mail to specialised databases and presentations at forumsfor practitioners working in the field of diabetes. We in-
cluded men and women over the age of 18 years of age
with prediabetes or ‘controlled’ type 2 diabetes. Prediabetes
is defined as having a fasting plasma glucose (FPG) level
of <7.0 and 2 hr plasma glucose load level ≥ 7.8 and <11.0).
‘Controlled’ diabetes is not a standard medical diagnosis
and was defined for the purpose of this study as people
diagnosed within the last five years, whose diabetes was diet
and exercise controlled and were not on any medication to
control their blood glucose levels. Selection criteria were
designed to ensure a heterogeneous population. We
excluded individuals with conditions or treatments that
would interfere with participation or completion of the
protocol such as an underlying disease likely to limit life
span or increase the risk of the intervention, or that had
a confounding effect on the outcomes of the study, such
as medication or a disease related to metabolism such
as Cushing's syndrome. Baseline characteristics on age,
sex, ethnicity, family history of diabetes, history of
hypertension, smoking or use of cholesterol lowering or
anti-hypertensive medication were collected at enrolment
using an interviewer administered questionnaire.
Recruitment took place from June 2007 to December
2009. A formidable recruitment challenge was that predia-
betes is asymptomatic and not recognised as a potentially
serious condition. The trial was approved by the Human
Research Ethics Committee at the University of Western
Sydney, Australia. All participants gave written informed
consent. This trial is registered with the Australian and
New Zealand Clinical Trials Registry.
Randomisation
A computer-generated randomisation list was used for
treatment allocation in a 1:1 ratio. Randomisation was
conducted by the UWS trial coordinator who was external
to the trial. Participants and investigators were masked to
group assignment. Unequal group size may have arisen
due to one treatment occurring with greater frequency at
the beginning of the randomisation list, as the study was
terminated midway through the list [8]. The medication
was sealed in sequentially numbered identical packets
according to the allocation sequence. The UWS trial co-
ordinator supplied labelled packets of the interventions as
required. Participants and investigators were blind to the
treatment allocated until the completion of data analysis.
Herbal intervention and treatment schedules
Jiangtang Xiaozhi is comprised of six commonly used
herbs. The herbs and dosage are shown in Table 1. The
placebo and intervention were identical in appearance,
taste and smell.
Both the Jiangtang Xiaozhi Capsule and the placebo
were manufactured in China by Tianjin Zhongxin
Pharmaceutical Group Corporation Ltd, a pharmaceutical
Table 1 Composition of Jiangtang Xiaozhi capsules
Ingredient Individual tablet Dosage of 3 tablets %
Nu Zhen Zi (Ligustrum lucidum Ait.; Oleaceae; privet fruit) 1.33 4.00 35%
Huang Qi (Astragalus membranaceus (Fisch.) BGE; Fabaceae; milk vetch root) 0.67 2.00 18%
Huang Lian (Coptis chinensis Franch.; Ranunculaceae; coptis rhizome) 0.33 1.00 9%
Li Zhi He (Litchi chinensis SONN.; Sapindaceae; lyechee nut) 0.67 2.00 18%
Kun Bu (Ecklonia kurome OKAM.; Alariaceae; kelp) 0.06 0.17 1%
Jiang Huang (Curcuma longa L.; Zingiberaceae; tumeric rhizome) 0.50 1.50 13%
Lactose 0.02 0.05 1%
Magnesium stearate 0.21 0.64 6%
Total 3.79 g 11.36 g 100%
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Manufacturing Practice (GMP) license issued by the
Therapeutic Goods Administration (TGA).
Participants were randomly allocated to receive either
3 Jiangtang Xiaozhi capsules or a placebo three times a
day for 16 weeks. Participants were asked not to alter
their diet or exercise habits during the intervention
period. This was monitored at monthly visits. A double
blind follow up visit was conducted 8 weeks after the
completion of the treatment.
Outcome measures
Primary outcomes were the change in fasting blood glucose
(FBG), post-prandial plasma glucose and glycosylated
haemoglobin (HbA1c) in the Chinese herbal medicine
group from baseline to the conclusion of the trial compared
to a placebo. Prediabetes is currently detected using FBG
and followed up with a 2 hr oral glucose tolerance test
(OGTT) to exclude diabetes [11]. The utility of HbA1c as a
measure to detect and monitor prediabetes is currently
being investigated and may supersede the combination of
FBG and the OGTT [12]. All three tests (FBG, 2 hr OGTT
and HbA1c) are highly correlated, therefore the inflation of
the experiment-wise error rate arising from multiple testing
will be slight [13]. The secondary outcomes were selected
with a view to helping explain the primary outcome results,
and shedding light on how the intervention might affect
other risk factors for diabetes. The secondary outcomes
were insulin, CRP protein, BMI and waist girth, lipids,
blood pressure and health-related quality of life.
Fasting blood glucose, insulin and CRP were collected
at 4 weekly intervals during the intervention. Post prandial
glucose as measured by an OGTT was collected at baseline,
trial completion (week 16) and at follow up (week 24).
Fasting blood glucose and the OGTT was conducted after
an overnight fast of at least 10–12 hours and 3 days of
carbohydrate loading using a standard 75-g oral glucose
tolerance test. HbA1c and lipids were measured at baseline,
weeks 8, 16 and 24. Blood pressure, weight and waist girth
were collected at weeks 0, 4, 8, 12, 16 and 24. Data onhealth related quality of life (HRQoL) was collected using
the 36-item short-form health survey Version 2 (SF-36v2)
at weeks 0, 16 and week 24 [14].
The Homeostatic model assessment (HOMA) was used
to assess beta-cell dysfunction and insulin resistance [15].
HOMA%S is a measure of insulin sensitivity, HOMA%B is
a measure of beta-cell function, and HOMA-IR is a meas-
ure of insulin resistance. The results of all three measures
need to be reported together for proper interpretation.
HOMA was selected as the model to use in this trial for
two reasons. Firstly, it has been widely used and validated
in a number of studies and has been found to correlate well
with the euglycaemic clamp method [16]. Secondly, the
sampling is simple, inexpensive and non-intrusive.
Statistical analyses
We calculated the sample size required to detect an effect
size of 0.6 (i.e. mean change in the outcome variable over
time differs by at least 0.6 standard deviations between the
two groups), at the α = 0.05 significance level, with 80%
power to be 45 per group. An effect size of 0.6 is generally
viewed as a medium to large effect. We sought to enrol 50
per group to allow for 10% withdrawal and non-compliance.
These calculations were based on the changes found
in an earlier study of Jiangtang Xiaozhi in people with
diabetes [9].
Descriptive statistics and independent samples t-tests
and 95% confidence intervals were used to compare
the baseline characteristics of the two study groups
(active treatment and placebo). All variables were visu-
ally inspected for normality. Fasting insulin, HOMA-IR,
HOMA insulin sensitivity and HOMA beta cell were non-
normally distributed. These data were log transformed to
improve kurtosis and skewness before applying parametric
statistical tests. HOMA estimates are usually not normally
distributed [17]. Results were back transformed for
presentation in the tables. The primary research objective
was to compare change in glycaemic control after 16 weeks
of treatment with either Jiangtang Xiaozhi capsules or
placebo. Unless otherwise indicated, results are presented
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covariance (ANCOVA) was used to model outcome at
16 weeks, by treatment group corrected for baseline
level of the outcome variable. Each outcome variable was
modelled separately. Baseline referred to data collected
before any treatment was received. Post-hoc testing using
pairwise comparisons of the estimated marginal means
was used for within group analysis across the trial phases.
Statistical analyses were performed using SPSS for
Windows version 17 (SPSS, Chicago, IL). A p value of <0.05
was considered statistically significant. Last observation
carried forward (LOCF) was used for missing observations.
Results
A total of 458 subjects were assessed for eligibility and
71 subjects were enrolled, 39 were randomised to the
intervention group and 32 to the placebo group. Eight
randomly allocated participants did not complete the
study; four in each group (see Figure 1).
Baseline characteristics are listed in Table 2. There was
no significant difference between the Jiangtang Xiaozhi and
placebo groups on age, sex, ethnicity, family history of
diabetes, history of hypertension, smoking or use of choles-
terol lowering or anti-hypertensive medication. Although
the placebo group appeared to be heavier than the inter-
vention group, there was no significant difference in BMI
between the placebo (32.0 ± 8.0) and the CHM (29.8 ±4.9)
groups (p =0.17). Measures of glycaemic control (FBG, two
hr postprandial glucose and HbA1C) were similar acrossRandomisation 
n=71
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Figure 1 Participant flow through recruitment to trial completion.groups at baseline. Insulin resistance as calculated by
HOMA-IR was not significantly different (p =0.37) be-
tween groups at baseline; mean levels were 2.12 ± 1.30
and 1.63 ± 0.91 in the placebo and CHM groups respect-
ively. Forty-one patients were classified as having IGT and
30 with ‘controlled’ diabetes.
Fasting blood glucose
An analysis of covariance (ANCOVA), found that fasting
blood glucose was not significantly different (p =0.73) at
the completion of the treatment (Week 16) between the
Jiangtang Xiaozhi group (6.3 ±1.1 mmol/L) and the placebo
group (6.7 ± 1.3 mmol/L) (Table 3). No significant differ-
ences were detected between baseline and week 16 values
within either the placebo or the Jiangtang Xiaozhi group
for fasting blood glucose (placebo p =0.85; Jiangtang
Xiaozhi p =0.85).
2 hr post prandial blood glucose levels were not
significantly different between groups at the completion of
treatment in week 16 (p =0.51) (Table 2). However, 2 hr
postload glucose tended to decrease in the Jiangtang
Xiaozhi group compared to baseline (p =0.03).
Insulin
There was a significant difference between the placebo
and the Jiangtang Xiaozhi group (p =0.04) at week 16.
Mean levels of insulin at the end of the intervention,
shown in Table 3, were 22.1 ± 25.9 mmol/L in the placebo
group and 11.6 ± 5.5 mmol/L in the Jiangtang XiaozhiIneligible n=382
Main reasons for ineligibility: 
FBG too high or too low; or on 
medication for FBG. Decided 





sufficient treatment effect n=2
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Lost contact n=1
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n=35
Table 2 Baseline demographic and clinical variables
Variable Placebo JTXZ
(n = 32) (n = 39)
Age and Sex
Male/Female - n 18/14 15/24
Age - mean (range) age (years) 59.9 (40–75) 58.3 (36–83)
Plasma glucose - mmol/L (SD)
Fasting 6.7 (1.0) 6.3 (.9)
Two hours after an oral glucose load 11.0 (2.9) 10.5 (2.3)
Glycosylated haemoglobin -% (SD) 6.4 (.7) 6.3 (.6)
Glycosylated haemoglobin - n ≥ 7% 6 5
Fasting insulin - mmol/L (SD) 15.5 (9.7) 11.8 (6.9)
Serum lipids - mmol/L (SD)
Total cholesterol 4.5 (.9) 4.9 (1.0)
Triglycerides 1.7 (.9) 1.7 (1.3)
HDL cholesterol^ 1.3 (.4) 1.5 (.4)
C-reactive protein - mg/L (SD)^ 6.7 (5.3) 6.7 (7.6)
Systolic blood pressure - mmHg (SD)^ 134.4 (14.0) 124.5 (13.3)
Diastolic blood pressure - mmHg (SD)^ 81.7 (15.9) 76.4 (11.1)
Body mass index - kg/m2 (SD) 32 (8.0) 29.8 (4.9)
Weight - kg (SD) 92.0 (28.5) 80.5 (15.1)
Waist - cm (SD)a 109.9 (22.1) 97.6 (11.1)
Waist-to-hip ratio - waist/hips (SD) .97 (.19) .88 (.07)
Diagnosed with type 2 diabetes - n 21 18
History of high lipids - n 18 23
Taking medication for cholesterol - n 14 15
Currently taking prescription medication - n 30 29
Currently taking vitamins, minerals or
herbal supplements - n
24 24
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insulin levels of the two groups was no longer apparent.
Due to the high standard deviation at week 16 in the
placebo group, data was examined for confounding factors
such as outliers. None were identified. Recall that data were
log transformed for ANCOVA and t-test analysis to address
skewness and kurtosis and ensure the requirements of the
statistical tests were met.
Insulin resistance and sensitivity
After 16 weeks of treatment, there was a trend toward
improved insulin resistance in the intervention group,
although this narrowly failed to reach statistical significance
(p = 0.06). HOMA-IR remained fairly steady in both groups
from baseline until Week 16 when an increase in levels was
observed in the placebo group. Levels in the placebo group
had returned to baseline levels at follow up. From baseline
to Week 24, there was no significant difference between the
two groups (p = 1.0).There was no significant difference between the two
groups in HOMA%B or HOMA%S levels at Week 16.
Insulin sensitivity within the placebo group declined
over the period of trial, although this failed to reach
statistical significance (p =0.35). In the Jiangtang Xiaozhi
group, insulin sensitivity improved moderately at the
outset of the trial, remained stable and returned to simi-
lar pre-treatment levels at Week 24. The placebo group
showed a slight decline in insulin sensitivity but returned
to pre-treatment levels by Week 24. Mean levels were
70.3 ± 39.2 and 74.4 ± 41.1 in the placebo and Jiangtang
Xiaozhi groups respectively.
Cholesterol
For HDL cholesterol, there was a significant improvement
in the Jiangtang Xiaozhi group compared to placebo at the
end of the treatment period (p = 0.03). Mean levels in the
placebo group had slightly decreased (1.24 ± 0.30 mmol/L)
compared to baseline and increased in the Jiangtang
Xiaozhi group (1.54 ± 0.53 mmol/L). At follow up, there
was no longer a significant difference between the two
groups at follow up at week 24 (p = 0.11).
There was no significant difference in total cholesterol
(p = 0.46) or triglycerides (p = 0.92) between the treatment
and placebo group at the completion of the treatment
phase of the trial.
Quality of life
We found no post-treatment in any of the eight dimensions
of the SF-36 between the Jiangtang Xiaozhi group and the
placebo group. It is of interest, however, that our clinical
trial cohort had poorer quality of life on three of the eight
dimensions of the SF-36: vitality, role limitations due to
emotional problems and mental health when compared
with the age relevant cohort (55–64 yrs) and all-age
Australian norms [18].
Other measures
At 16 weeks, there was no significant difference between
the two groups on BMI, waist circumference, CRP, blood
pressure or HRQoL. No differences were found at follow
up eight weeks later.
Behaviour change in physical and dietary habits was
measured at different time intervals throughout the trial
as it is known to affect blood glucose and insulin levels.
There was no significant change in any group on nutri-
tional intake or physical activity from baseline to the
completion of the trial.
Safety and adverse events
The liver function of all participants was assessed at the
baseline and throughout the trial to monitor for any
possible adverse reactions. Jiangtang Xiaozhi was well
tolerated with no serious adverse events. There were
Table 3 Clinical measures
Parameter Jiangtang Xiaozhi Placebo P
Baseline Week 16 Baseline Week 16
Fasting blood glucose (mmol/L) 6.3 ± 0.9 6.3 ± 1.1 6.7 ± 1.0 6.7 ± 1.3 0.70
Postprandial blood glucose (mmol/L) 10.45 ± 2.3 9.66 ± 2.6* 10.98 ± 2.9 10.60 ± 3.4 0.51
HbA1c (%) 6.4 ± 0.7 6.5 ± 0.7 6.3 ± 0.6 6.4 ± 0.6 0.62
Insulin (mmol/L) 11.8 ± 6.9 11.6 ± 5.5 15.5 ± 9.7 22.1 ± 25.9 0.04
HOMA-IR 1.63 ± 0.91 1.58 ± 0.74 2.06 ± 1.28 2.43 ± 1.59 0.06
HOMA%B 81.52 ± 34.5 83.5 ± 38.1 86.51 ± 36.78 98.83 ± 48.29 0.26
HOMA%S 81.84 ± 48.12 79.72 ± 44.14 72.78 ± 46.42 62.67 ± 38.48 0.34
Total cholesterol (mmol/L) 4.91 ± 1.03 4.96 ± 0.94 4.47 ± 0.85 4.56 ± 0.81 0.46
HDL cholesterol (mmol/L) 1.45 ± 0.44 1.54 ± 0.53 1.28 ± 0.30 1.24 ± 0.30 0.03
Triglycerides (mmol/L) 1.6 ± 0.64 1.6 ± 0.76 1.67 ± 0.93 1.59 ± 0.86 0.92
C-reactive protein (mg/L) 6.7 ± 7.6 4.66 ± 1.77 6.73 ± 5.25 5.18 ± 3.0 0.36
Weight (kg) 80.5 ± 15.1 80.4 ± 15.0 92.0 ± 28.5 91.8 ± 28.6 0.84
BMI (kg/m2) 29.8 ± 4.9 31.0 ± 1.8 32.0 ± 8.0 31.2 ± 1.8 0.64
Waist (cm) 97.6 ± 11.1 98.6 ± 12.4 109.9 ± 22.1 106.3 ± 18.6 0.05
Systolic blood pressure (mmHg) 124.5 ± 13.3 124.1 ± 15.5 134.4 ± 14.0 130.1 ± 16.1 0.96
Diastolic blood pressure (mmHg) 76.4 ± 11.1 71.7 ± 8.6 81.7 ± 74.3 74.3 ± 2.2 0.96
All data are means ± SD unless otherwise stated.
*within group statistically significant.
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No fatalities or major adverse events occurred during
the trial. One participant in the intervention group
developed moderate dizziness within 24 hours of the
medication. The participant stopped the medication for
24 hours and the dizziness ceased. A rechallenge produced
similar symptoms and as a result the participant was
withdrawn from the trial. This patient was later found
to be in the Jiangtang Xiaozhi group.
Blinding was effective with only 25% of participants
correctly identifying their group in the first four weeks
and 27% in the final four weeks of the intervention.
Discussions and conclusions
Effect on blood glucose
In the present study, we found no significant differences
on any of the glycaemic outcome measures between the
Jiangtang Xiaozhi and placebo groups at completion of
the treatment. However, the study yielded three positive
findings on secondary outcomes. First, levels of insulin
resistance (HOMA-IR) were lower than those in the
placebo group. Second, serum insulin slightly decreased
in the treatment group compared to worsening levels in
the placebo group, resulting in a borderline significant
difference between groups. Third, HDL cholesterol was
significantly improved in Jiangtang Xiaozhi group com-
pared to the placebo. The absence of a detectable glycaemic
measures in this trial contradicts with the previous clinicaltrial. In this earlier trial in a group with type 2 diabetes,
plasma glucose levels reduced significantly from baseline
after 8 weeks treatment by −1.71 ± 2.52 mmol/L compared
to −0.72 ± 4.17 mmol/L in the pioglitazone group [9].
Postprandial plasma glucose and HbA1c also both
showed a significant difference compared to baseline
(11.41 ± 2.63 mmol/L to 9.91 ± 1.93 mmol/L and 7.35 ±
1.87% to 6.73 ± 1.02%, respectively). The reasons for this
discrepancy can be complex. However, possible explana-
tions may include: (a) this herbal medicine may be ineffect-
ive in treating elevated glucose levels in people with IGT;
(b) it may be that the size of the sample was not sufficiently
large to detect an effect, particularly given the transient
nature of IGT; (c) an effect might only occur with greater
symptom severity at baseline [19]. The fourth possibility is
that the dosage of Jiangtang Xiaozhi was not adequate. Our
clinical trial cohort was largely overweight and obese with a
mean BMI of 30.8 kg/m2, which may also affect the efficacy
of an intervention [20].
A significant improvement within the Jiangtang Xiaozhi
group on postprandial plasma glucose levels at the comple-
tion of the treatment was identified compared to baseline.
Measuring change from baseline is an acceptable and
meaningful statistic where baseline levels are comparable
between the intervention and placebo groups, which in our
case they were. Hyperglycaemia in prediabetes is primarily
postprandial in nature. The body is unable to control blood
glucose adequately after a loading of ‘sugar’. It is these
postprandial ‘spikes’ in blood glucose levels that are
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dysfunction [21]. Perhaps Jiangtang Xiaozhi may be of
assistance in reducing these ‘spikes’.
Effect on insulin
Insulin resistance is a decreased responsiveness of target
tissues - skeletal and myocardial myocytes, hepatocytes,
and adipocytes - to normal levels of circulating insulin
(Setsi 2006). In our placebo group, higher levels of insulin
resistance (HOMA-IR) accompanied higher levels of serum
insulin. This is to be expected. Greater serum insulin levels
are seen in those with higher insulin resistance. A smaller
insulin response is anticipated in those with better insulin
sensitivity. At week 16 of treatment, there was a trend for
insulin resistance to improve in the Jiangtang Xiaozhi
group compared to the placebo group, but the change
narrowly missed statistical significance.
However, the level of change detected in insulin resist-
ance in our trial may only have marginal clinical signifi-
cance. Cut-off values for normal HOMA-IR are considered
to lie somewhere between 2.5 and 4.1 [17,22,23]. At these
values our clinical trial cohort would be considered to be in
the non-clinical range at the start of the trial with levels of
2.12 ± 1.30 and 1.60 ± 0.92 in the placebo and Jiangtang
Xiaozhi groups respectively. The 3 month clinical trial of
the herbal extract, berberine, found a clinical and statisti-
cally significant difference with HOMA-IR reducing from
3.9 to 2.44 in people with diabetes not IGT [24]. Perhaps
our clinical trial cohort was overall too well at baseline and
our sample did not allow for sufficient power to detect
change from these baselines.
In the present study, mean beta-cell function (HOMA%B)
increased in the placebo group from 87% to 99% but not to
a statistically significant degree while remaining stable in the
Jiangtang Xiaozhi group (82% to 84%). These results could
be interpreted as a trend towards improvement in the
beta-cell function of the placebo group. However, beta-cell
function needs to be interpreted in the context of serum
insulin, insulin sensitivity and insulin resistance.
Typically a beta-cell or HOMA%B value that is closer
to 100% is associated with better beta-cell function
[17,25-27]. Why then in the placebo group, compared to
the Jiangtang Xiaozhi group, would insulin secretion
increase, insulin sensitivity decrease but beta-cell function
(HOMA%B) appear to improve? One explanation may be
that a ‘high’ HOMA%B does not always equate to better
beta-cell functioning but perhaps the opposite.
When insulin sensitivity is improved, beta-cell activity
may be reduced – the beta-cells of the pancreas simply
don’t have to work as hard anymore [17]. This explanation
is supported by several longitudinal studies which have
shown that decreased beta-cell function as represented by
HOMA%B does not, on its own, seem to predict the
development of diabetes. A five year study of 12,924non-diabetic Koreans examined the role of HOMA%B
in predicting the development of diabetes. They found
that the HOMA%B baseline value was actually higher
in those who went on to develop diabetes [28]. Another
study which utilised HOMA to predict the development
of diabetes concluded that whereas low insulin secretion
may be adequate for an insulin sensitive patient, the same
level of beta-cell function may be inadequate for another
patient [29]. The developers of the HOMA instrument
have indeed pointed out that “HOMA-%B is a measure of
beta-cell activity, not of beta-cell health or pathology” and
that HOMA%B values need to be considered alongside
HOMA%S and HOMA-IR [17]. Therefore what may have
been happening in the placebo group was the natural
progression of diabetes: an increase in insulin secretion
combined with a rise in beta-cell activity (HOMA%B)
coupled with a rise in insulin resistance (HOMA-IR)
indicating that the beta-cells are working harder. Whereas
in the Jiangtang Xiaozhi group the insulin measures,
stable serum insulin, stable insulin sensitivity and reduced
insulin resistance compared to the worsening insulin
measure in the placebo group indicate that progression
has perhaps stalled but not reversed.
Nonetheless, the degree to which the intervention
appeared to maintain insulin sensitivity levels, restrain
insulin secretion and thereby help preserve beta-cell
function does warrant further investigation. Worsening
of impaired glucose tolerance, progressing to frank
diabetes is generally accepted as a consequence of
insulin resistance, impaired insulin secretion and pan-
creatic beta-cell failure [30-32]. While the relative con-
tribution of each of these factors is still a subject for
debate, we do know that insulin resistance plays a key
role and this is evidenced by a number of longitudinal
and cross-sectional studies.
Effect on cholesterol
People with diabetes often have abnormally low levels of
HDL cholesterol and high levels of triglycerides [33].
There is also a strong association between dyslipidaemia
and insulin resistance [34]. We found that high-density
lipoprotein cholesterol (HDL), otherwise known as the
‘good’ cholesterol, improved post-treatment in the
Jiangtang Xiaozhi group compared to the placebo group.
Cholesterol lowering medication was being taken by
nearly all our clinical trial participants. When analysed
as a covariant there was no significant effect exerted by
cholesterol lowering medication consumption on any of
the lipid results.
The mean post-treatment increase of 0.10 mmol/L in
HDL-cholesterol in the Jiangtang Xiaozhi group repre-
sents a 6% change from baseline and is thus of some
clinical significance. In a pooled analysis of four clinical
trials of statins, individuals with a ≥7.5% increase in HDL
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incidence of coronary atherosclerosis [35].
A new approach toward treating dyslipidaemia alongside
high blood glucose levels has been to target insulin resist-
ance [36]. Thus, a possible explanation for the improved
HDL levels in the Jiangtang Xiaozhi group may have been
improved insulin resistance. Our results indicate Jiangtang
Xiaozhi both improves HDL levels and stabilises insulin.
This is a particularly encouraging clinically relevant finding
as it signifies the potential of the Jiangtang Xiaozhi to
treat two conditions and thus avoid some of the problems
inherent with polypharmacy.
Limitations of our study
Our study has several limitations. Firstly, our sample size
may have lacked sufficient statistical power to detect a
clinically significant change in FBG and to adequately
account for the transient nature of people with IGT [19].
Secondly, the intervention period may have been too short
to allow for the natural progression of impaired glucose
tolerance. A further limitation relates to the methodology
of the outcome measures. We used HOMA to assess insu-
lin resistance and sensitivity as a cost effective method with
validity for clinical trials. The use of the euglycaemic clamp
method to assess insulin sensitivity may have provided a
more accurate result. Clamp methods are not feasible in
large studies. Likewise we used only one insulin measure
and this may not have sufficiently accounted for intra-
individual variation. A final limitation was dosage. The
dosage used in our trial was significantly less than that
used in the trial of Jiangtang Xiaozhi in people with
diabetes (34 grams per day compared to 75 grams per
day in the first study). It is also likely that therapeutic
doses weren’t reached by some participants. The regime of
three tablets three times a day is a difficult dosage regime.
Although a final pill count was undertaken not all partici-
pants returned leftover medication. Simpler, less frequent
dosing regimens result in better compliance [37].
In summary, although Jiangtang Xiaozhi did not sig-
nificantly change blood glucose levels, the intervention
was associated with some positive effect on insulin and
HDL. The positive results of Jiangtang Xiaozhi in reducing
postprandial glucose indicate that a higher level of baseline
severity in blood glucose symptoms might yield more reli-
able findings. Our analysis was considerably underpowered.
A longer study, in line with other interventions in this
population group, to allow for the natural progression of
the disease may also bring forth an effect on fasting blood
glucose. The strength of this study was that it was a ro-
bust double-blinded, placebo controlled trial conducted
according to rigorous scientific methodology.
The safety of this herbal formulation and its components
has been demonstrated in animal and human studies.
The lack of, or minimal, side effects provide a considerableadvantage over many of the current pharmaceutical
treatments used for the treatment of prediabetes and
controlled diabetes.
In light of the growing epidemic of diabetes worldwide,
preventing or delaying the onset of diabetes may likewise
reduce the microvascular and macrovascular complications
of the disease. It is worthwhile investigating the potential
of Jiangtang Xiaozhi to decrease blood glucose levels and
reduce or prevent the incidence of diabetes in a longer,
adequately powered trial.
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